Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Owain Saunders"'
Autor:
Niall James Davison, Darren Burns, Bram Ramaekers, Daniel Gladwell, Owain Saunders, Indeg Sly, Rose Hart, Theresa Cain, Shijie Ren, Dawn Lee, William Sullivan
Publikováno v:
Pharmacoeconomics, 38(7), 765-776. Adis International Ltd
Introduction\ud \ud Health economics models are typically built in Microsoft Excel® owing to its wide familiarity, accessibility and perceived transparency. However, given the increasingly rapid and analytically complex decision-making needs of both
Autor:
Miranda Cooper, Owain Saunders, Paul G. Richardson, Edward A. Stadtmauer, Vera J. Suman, Philip L. McCarthy, Sergio Giralt, Sarah A. Holstein, Sujith Dhanasiri, Kenneth C. Anderson
Publikováno v:
Blood. 132:4737-4737
Background: The phase 3 double-blind, CALGB/Alliance 100104 study assessed the efficacy and safety of lenalidomide (LEN) or placebo maintenance therapy until relapse in post-autologous stem cell transplantation (ASCT) patients with newly-diagnosed mu
Autor:
Kevin Hong, Katja Weisel, Craig J. Gibson, Mohamed H. Zaki, Meletios A. Dimopoulos, Owain Saunders, Kevin W. Song, Philippe Moreau, Lars Sternas
Publikováno v:
Leukemialymphoma. 57(12)
Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS). Pomalidomide plus low-dose dexamethasone (POM + LoDEX) significantly extends OS in RRMM vs. high-dose dexamethasone. Survival of patients with stable disease (SD) w
Autor:
Cornelis J. A. Punt, Petronella O. Witteveen, Jane Robertson, Juliane M. Jürgensmeier, Hester van Cruijsen, Emile E. Voest, Thomas A. Puchalski, Martijn R. Meijerink, Giuseppe Giaccone, Klaas Hoekman, Owain Saunders, Carla M.L. van Herpen
Publikováno v:
van Cruijsen, H, Voest, E E, Punt, C J A, Hoekman, K, Witteveen, P O, Meijerink, M R, Puchalski, T A, Robertson, J, Saunders, O, Jurgensmeier, J M, van Herpen, C M L & Giaccone, G 2010, ' Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours ', European Journal of Cancer, vol. 46, no. 5, pp. 901-911 . https://doi.org/10.1016/j.ejca.2009.12.023
European journal of cancer (Oxford, England, 46(5), 901-911. Elsevier Limited
European Journal of Cancer, 46(5), 901-911. Pergamon
European Journal of Cancer, 46, 901-11
European Journal of Cancer, 46, 5, pp. 901-11
European journal of cancer (Oxford, England, 46(5), 901-911. Elsevier Limited
European Journal of Cancer, 46(5), 901-911. Pergamon
European Journal of Cancer, 46, 901-11
European Journal of Cancer, 46, 5, pp. 901-11
Contains fulltext : 89775.pdf (Publisher’s version ) (Closed access) AIM: Cediranib is a highly potent inhibitor of vascular endothelial growth factor receptor (VEGFR) signalling. Preclinical and clinical data suggest that inhibition of the VEGFR a
Autor:
Klaus Mross, Owain Saunders, Juliane M. Jürgensmeier, Jane Robertson, Ralph Strecker, Patrizia Siegert, Hubert E. Blum, Jan Harder, Clemens Unger, Helen Young, Michael Medinger, Joachim Drevs, Ute Zirrgiebel, Thomas A. Puchalski
Publikováno v:
Journal of Clinical Oncology. 25:3045-3054
Purpose AZD2171 is a highly potent oral selective inhibitor of vascular endothelial growth factor (VEGF) signaling. This phase I study was designed to evaluate the safety and tolerability of increasing doses of AZD2171, with additional assessments of
Autor:
Owain Saunders, Kevin W. Song, Katja Weisel, Philippe Moreau, Craig J. Gibson, Mohamed H. Zaki, Lars Sternas, Kevin Hong, Meletios A. Dimopoulos
Publikováno v:
Journal of Clinical Oncology. 33:8593-8593
8593 Background: RRMM patients (pts) previously exposed to bortezomib (BORT) and lenalidomide (LEN) have short overall survival (OS). The phase 3 MM-003 trial (NCT01311687) demonstrated significant...
Autor:
G. Giaccone, Emile E. Voest, C.J.A. Punt, C.M.L. van Herpen, H. van Cruijsen, Marlies H.G. Langenberg, Owain Saunders, Petronella O. Witteveen, Jane Robertson, Klaas Hoekman
Publikováno v:
European Journal of Cancer Supplements. 5:108-109
Autor:
Jane Robertson, J.-Y. Douillard, Geert R. D'Haens, David Cunningham, R. P. W. Wong, Owain Saunders, E. Van Cutsem, A. M. Stone
Publikováno v:
Journal of Clinical Oncology. 26:4028-4028
4028 Background: Cediranib (AZD2171) is an oral, highly potent and selective inhibitor of VEGF signaling, with activity against VEGFR-1, -2, and -3. Recent trials have shown that the combination of...
Autor:
Owain Saunders, Ute Zirrgiebel, H. van Cruijsen, Emile E. Voest, Jane Robertson, C.M.L. van Herpen, J. Drevs, Clemens Unger, C.J.A. Punt, G. Giaccone
Publikováno v:
Journal of Clinical Oncology. 25:3560-3560
3560 Background: Antiangiogenic agents have recently demonstrated promising activity in patients with advanced RCC. AZD2171 is an oral, highly potent and selective inhibitor of VEGFR-1, -2 and -3 tyrosine kinases, and is currently in Phase II/III dev